UCB's Global Corporate Website

This section is intended for media and financial analysts

Our Shareholders

Since 13 March 2014, UCB’s capital amounts to € 583 516 974, divided in 194 505 658 ordinary shares with no nominal value.

The main shareholder of UCB is Financière de Tubize SA, a Belgian company listed on Euronext Brussels.

Shareholder Structure

Source

Latest notifications and shareholder identification (as of January 2023), UCB underlying ownership analysis

close

62% Free Float

Institutional investors:
Geographic distribution

Shareholders' Meetings

The Ordinary General Meeting of Shareholders is held on the last Thursday of April at 11:00 CET.

The next shareholders' meeting takes place on

25 April 2024

Shareholders' Meeting Archives


 


 

Consensus

Estimates based on Visible Alpha consensus1 dated 30.11.2023.

Estimates include 13 broker models2 collaborating with Visible Alpha.

UCB FY Consensus Earnings Estimates (Average)
In € million 2022a 2023e 2024e 2025e  2026e 2027e 2028e
Net Sales 5,140 4,869 5,406 6,059 6,454 6,863 7,213
Revenue 5,517 5,218 5,703 6,349 6,740 7,125 7,503
Adjusted EBIT 675 578 817 1,312 1,514 1,719 1,817
Adjusted EBITDA 1,260 1,207 1,472 2,003 2,207 2,383 2,460
Adj. EBITDA ratio 22.8% 23.1% 25.8% 31,6% 32,8% 33,4% 32,8%
Net Profit 418 329 538 980 1,145 1,293 1,357
Core EPS (€) 4.37 3.63 4.73 7.16 8.02 8.86 9.39
UCB FY Consensus Product Sales Estimates (Average)
In € million 2022a 2023e 2024e 2025e  2026e  2027e  2028e
Product Portfolio              
Cimzia 2,085 2,063 1,997 1,866 1,636 1,360 1,184
Bimzelx 35 162 506 952 1,455 1,945 2,377
Evenity* 25 58 99 131 160 185 207
Rystiggo   20 81 168 269 360 421
Zilbrysq   19 137 249 421 561 671
Vimpat 1,124 410 332 272 231 207 182
Keppra 729 627 561 516 477 443 417
Briviact 485 569 646 706 486 343 306
Neupro 305 281 252 220 202 185 164
Fintepla 116 236 382 508 623 721 671
Nayzilam 78 98 119 137 146 155 141
Potential New Products non-risk adjusted        
Dapirolizumab pegol       70 142 253 283
Staccato alprazolam     21 37 77 123 146
Bepranemab         5 120 156
Minzasolmin             130
doxTM / MT1621     15 39 79 111 124

*European sales, ex-EU sales booked by Amgen/Astellas

1Disclaimer

The information provided by Visible Alpha cited herein provided “as is” and “as available” without warranty of any kind. Use of any Visible Alpha data is at your own risk and Visible Alpha disclaims any liability for use of the Visible Alpha data.
Although the information is obtained or compiled from reliable sources Visible Alpha neither can nor does guarantee or make any representation or warranty, either express or implied, as to the accuracy, validity, sequence, timeliness, completeness or continued availability of any information or data, including third-party content, made available herein.
In no event shall Visible Alpha be liable for any decision made or action or inaction taken in reliance on any information or data, including third-party content. Visible Alpha further explicitly disclaims, to the fullest extent permitted by applicable law, any warranty of any kind, whether express or implied, including warranties of merchantability, fitness for a particular purpose and non-infringement.

close

2Contributing brokers

Broker Model date
Berenberg 01-Aug-2023
BNPP Exane 04-Aug-2023
BofA 12-Sep-2023
Citi 06-Jul-2023
Cowen 25-Oct-2023
Deutsche Bank 09-Nov-2023
HSBC 15-Aug-2023
ING 07-Nov-2023
Jefferies 25-Oct-2023
Kepler 02-Aug-2023
Morgan Stanley 08-Nov-2023
Redburn 08-Nov-2023
UBS 23-Oct-2023

 

close

 

Dividends

The Board intends to continue to sustain a dynamic dividend policy, consistent with the long-term growth prospects of the Company, offering gradual increase in dividend, and as far as possible not to reduce it, irrespective of the short-term income variations.

The Board of Directors proposed to pay a gross dividend of € 1.33 per share (gross), which was approved by the annual general meeting of the shareholders.

  • Coupon # 26
  • Ex-dividend: 28 April 2023
  • Record date: 2 May 2023
  • Payment: 3 May 2023

Coupon # 26 of UCB shares is payable at € 0.931 net per share after deduction of Belgian withholding tax of 30%*, via our paying agent, KBC Bank NV.

* Lower withholding tax rates may be applicable depending on the specific situation of each shareholder.